Enhancing target antigen specificity to reduce antibody-drug conjugate toxicity in solid cancer treatment
19 Feb 2025
Antibody Drug Conjugates
- What challenge do ADCs face due to the presence of target antigens on healthy cells?
- How does heterogeneous expression of target antigens in solid tumors impact the efficacy and safety of ADCs?
- What role does the extracellular matrix (ECM) and poor vascularization in solid tumors play in ADC delivery?
- What risks are associated with the premature release or degradation of cytotoxic payloads in ADCs?
- How can ADCs potentially trigger immune responses, and what are the associated risks to healthy tissues?
Industry Expert
